Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBOC-201 for Wound Healing in Lower Limb Amputation
NCT00300040Phase 2Terminated
- Sponsor
- Biopure
- Start
- May 2006
- Primary completion
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of hemoglobin glutamer-250 in critical limb ischemia (CLI) (2 arms), sponsored by Biopure. Primary endpoint: Mortality at 60 days post amputation procedure. Started May 2006; status: terminated.
02
Drugs
hemoglobin glutamer-250
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT00300040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300040.